XML 9 R3.htm IDEA: XBRL DOCUMENT v3.25.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total revenue $ 801.4 $ 721.7
Total cost of revenue 410.2 368.9
Gross profit 391.2 352.8
Operating expenses:    
Selling, general and administrative 225.4 195.3
Research and development 97.1 81.8
Other charges, net 36.9 10.9
Total operating expenses 359.4 288.0
Operating income 31.8 64.8
Interest and other income (expense), net (6.7) 6.8
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries 25.1 71.6
Income tax provision 8.7 19.8
Equity in income of unconsolidated investees, net of tax 0.4 0.2
Consolidated net income 16.8 52.0
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries (0.6) 1.1
Net income attributable to Bruker Corporation $ 17.4 $ 50.9
Net income per common share attributable to Bruker Corporation shareholders:    
Basic $ 0.11 $ 0.35
Diluted $ 0.11 $ 0.35
Weighted average common shares outstanding:    
Basic 151.6 145.2
Diluted 151.9 145.9
Product    
Total revenue $ 643.3 $ 586.9
Total cost of revenue 322.3 291.7
Service and other revenue    
Total revenue 158.1 134.8
Total cost of revenue $ 87.9 $ 77.2